AstraZeneca/BMS's Dapagliflozin Needs European Epidemiological Study, But Headed For Strong Label
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe's CHMP takes divergent stance to FDA on dapagliflozin, clearing it for treating diabetes if AstraZeneca and Bristol-Myers Squibb conduct a post-marketing study. The committee also cleared ruxolitinib and ferumoxytol, but rejected Folotyn, for EU marketing.
You may also be interested in...
Europe’s CHMP Clears Sofosbuvir, Dolutegravir And Dalamanid
As well as new therapies for hepatitis C, HIV/AIDS and tuberculosis, the EU's CHMP issued a positive opinion on new active substance status for Biogen Idec's oral MS therapy dimethyl fumurate after the panel’s latest meeting.
Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission
Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.
Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission
Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.